Intervention Review

You have free access to this content

Beclometasone for chronic obstructive pulmonary disease

  1. Daan A De Coster1,*,
  2. Melvyn Jones2,
  3. Nikita Thakrar3

Editorial Group: Cochrane Airways Group

Published Online: 9 OCT 2013

Assessed as up-to-date: 6 FEB 2013

DOI: 10.1002/14651858.CD009769.pub2


How to Cite

De Coster DA, Jones M, Thakrar N. Beclometasone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD009769. DOI: 10.1002/14651858.CD009769.pub2.

Author Information

  1. 1

    University College London, Upper 3rd Floor, UCL Medical School (Royal Free Campus), Department of Primary Care and Population Health, London, UK

  2. 2

    UCL, Department of Primary Care and Population Health, Division of Population Health, Faculty of Population Health Sciences, London, UK

  3. 3

    UCL, Department of Primary Care and Population Health, London, UK

*Daan A De Coster, Department of Primary Care and Population Health, University College London, Upper 3rd Floor, UCL Medical School (Royal Free Campus), Rowland Hill Street, London, NW3 2PF, UK. d.coster@ucl.ac.uk. decosterdaan@googlemail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 9 OCT 2013

SEARCH

[Figure 1]
Figure 1. PRISMA study flow diagram.
[Figure 2]
Figure 2. Detailed break-down of results of the search strategy.
[Figure 3]
Figure 3. Risk of bias graph: review authors' judgements about all risk of bias items presented as percentages across all included studies.
[Figure 4]
Figure 4. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Beclometasone versus placebo, Outcome 1 Change in FEV1.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Beclometasone versus placebo, Outcome 2 Mortality (dichotomous Peto method).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Beclometasone versus placebo, Outcome 3 Exacerbations: mean rate (rate ratio).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Beclometasone versus placebo, Outcome 4 Symptoms: change in dyspnoea scale (Fletcher Scale).
[Analysis 1.5]
Analysis 1.5. Comparison 1 Beclometasone versus placebo, Outcome 5 Adverse events.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Beclometasone versus placebo, Outcome 6 Withdrawal.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 1 Change in FEV1.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 2 Mortality (all-cause) (dichotomous Peto method).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 3 Pneumonia: participants with at least one (dichotomous Peto odds ratios).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 4 Change in exercise capacity: 6MWT.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 5 Exacerbations: participants with at least one (dichotomous).
[Analysis 2.6]
Analysis 2.6. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 6 Exacerbations (hospitalisations): participants with at least one (dichotomous).
[Analysis 2.7]
Analysis 2.7. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 7 Exacerbations (hospitalisations): mean rate (rate ratio).
[Analysis 2.8]
Analysis 2.8. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 8 Number of hospitalisations (rate ratio).
[Analysis 2.9]
Analysis 2.9. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 9 Change in Quality of Life: SGRQ.
[Analysis 2.10]
Analysis 2.10. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 10 Symptoms: change in dyspnoea scale (modified Medical Research Council questionnaire).
[Analysis 2.11]
Analysis 2.11. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 11 Symptoms: change in BODE index.
[Analysis 2.12]
Analysis 2.12. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 12 Use of rescue bronchodilators: self-reported days without.
[Analysis 2.13]
Analysis 2.13. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 13 Adverse events.
[Analysis 2.14]
Analysis 2.14. Comparison 2 Beclometasone/formoterol versus formoterol, Outcome 14 Withdrawal.